Center for Dermatology Clinical Research,Inc

Fremont, California 94538

11 studies enrolling now · 80 studies all time

What they study most

Achrochordon, Acne Inversa, Acne Vulgaris, Actinic Keratosis, Alopecia Areata, Atopic, Atopic Dermatitis, Atopic Dermatitis (AD), Atopic Eczema, Chronic Pruritus, Cutaneous Lupus Erythematosus (CLE), Cutaneous Neurofibroma

Studies at this site

• A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo — Recruiting now
• A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss) — Recruiting now
• Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK) — Recruiting now
• Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib — Recruiting now
• A Study of Zasocitinib in Adults With Nonsegmental Vitiligo — Recruiting now
• A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis — Recruiting now
• Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis — Recruiting now
• A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO) — Recruiting now
• Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp — Recruiting now
• Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities — Recruiting now
• Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata — Recruiting now
• A Study of Barzolvolimab in Patients With Prurigo Nodularis — Running, not enrolling
• A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa — Running, not enrolling
• A Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC — Stopped early
• A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon) — Completed
• Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial — Completed
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo. — Stopped early
• A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata — Completed
• Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment With 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis — Completed
• Study of ENV-294 in Healthy Adults and in Adults With Moderate-to-Severe Atopic Dermatitis — Completed
• A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2) — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis. — Running, not enrolling
• A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo — Completed
• A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color — Completed
• Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE) — Stopped early
• NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) — Completed
• A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) — Completed
• Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis — Completed
• Using a Novel Skin Tag Removal Device — Running, not enrolling
• Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) — Completed
• A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis — Completed
• Skin Fluorescent Imaging (SFI) System in Patients With Nevi — Completed
• A Trial to Compare the Incidence of Squamous Cell Carcinoma (SCC) and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp — Stopped early
• This Study is to Assess the Efficacy of Difamilast Ointment in Mild to Moderate Atopic Dermatitis(AD) — Completed
• A Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in Mild to Moderate Atopic Dermatitis — Completed
• A Vehicle-controlled Study of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO) — Status unconfirmed
• Phase 2b Study of ASLAN004 in Adults With Moderate-to-Severe Atopic Dermatitis — Completed
• A Study of LY3471851 in Participants With Eczema — Completed
• A Study of LY3471851 in Participants With Psoriasis — Completed
• A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis — Completed
• Assessing Tissue Remodeling in the Skin Using SFI (Skin Fluorescence Imaging) — Completed
• Self-Administered Intralesional Injections for Acne — Status unconfirmed
• Intralesional Injections of Triamcinolone for Acne Vulgaris — Completed
• A Device Study for the Treatment of Acne — Completed
• A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA) — Completed
• Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis — Stopped early
• Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis (RADIANT) — Completed
• Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines — Completed
• A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa — Completed
• Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis — Completed